Apogenix is a leading biopharmaceutical company dedicated to developing groundbreaking protein therapeutics for the treatment of cancer and other malignant diseases. With a focus on immuno-oncology, Apogenix has created a promising portfolio of innovative drug candidates that target TNFSF-dependent signaling pathways. These candidates have shown great potential in reducing lymphopenia and inflammatory cell death in patients with viral infections, as well as restoring the anti-tumor immune response in cancer patients.

One of their most exciting drugs in development is APG101, which has demonstrated significant efficacy in a controlled phase II trial for recurrent glioblastoma. Additionally, Apogenix is actively involved in combatting the ongoing COVID-19 pandemic, with their lead immunotherapy candidate, asunercept, being evaluated in a phase II trial for COVID-19 patients. In addition to their therapeutic candidates, Apogenix has developed the proprietary HERA-ligand technology platform for the creation of novel fusion proteins.

These fusion proteins offer distinct advantages over traditional biologics and have immense potential in the field of oncology. Apogenix's innovative approach, dedication to scientific excellence, and commitment to transforming patient outcomes truly set them apart in the field of biopharmaceuticals